Lipopolysaccharide Binding Protein (LBP), a pivotal Type 1 acute phase protein primarily synthesized by the liver, plays a fundamental role in mediating the body’s response to lipopolysaccharide (LPS), a key component of the outer membrane of Gram-negative bacteria. LBP is inherently involved in the mechanism of LPS response, facilitating the transformation of LPS into monomers and orchestrating its transfer to cell surface receptor (s)CD14 and
various lipoproteins. This dual functionality positions LBP as a crucial player in both activating and neutralizing pathways of LPS response. It not only triggers the activation of monocytes, leading to the release of pro-inflammatory mediators but also contributes to the detoxification and clearance of LPS via lipoprotein-mediated uptake.
In healthy individuals, plasma LBP levels typically hover around 10 μg/ml, but these levels can surge by nearly tenfold during acute phase responses, reflecting its significant role in the body’s defense mechanism. The LBP assay offers a robust method for quantifying functional LBP in an array of sample types, including tissue culture supernatants, plasma, and serum, across various species.
This product is manufactured in Netherlands by Hycult Biotech.